tetano
Editor, Senior Moderator
Transplant Proc
. 2022 May 31;S0041-1345(22)00382-7.
doi: 10.1016/j.transproceed.2022.05.002. Online ahead of print.
Evaluation of the Correlation Between Responders and Non-Responders to the Second Coronavirus Disease Vaccination In Kidney Transplant Recipients: A Retrospective Single-Center Cohort Study
Masatoshi Matsunami[SUP] 1 [/SUP], Tomo Suzuki[SUP] 2 [/SUP], Shinnosuke Sugihara[SUP] 3 [/SUP], Takumi Toishi[SUP] 3 [/SUP], Kanako Nagaoka[SUP] 3 [/SUP], Junko Fukuda[SUP] 3 [/SUP], Mamiko Ohara[SUP] 3 [/SUP], Yayoi Takanashi[SUP] 4 [/SUP], Atsuhiko Ochi[SUP] 5 [/SUP], Jun Yashima[SUP] 4 [/SUP], Hiroshi Kuji[SUP] 6 [/SUP], Kosei Matsue[SUP] 7 [/SUP]
Affiliations
Abstract
Background: The immune response to COVID-19 vaccination in kidney transplant (KTx) recipients is significantly lower than that in healthy controls. We evaluated immune responses after the COVID-19 vaccine and their possible relationship with other cofactors in KTx recipients.
Methods: This retrospective single-center cohort study included 29 KTx recipients 2-8 weeks after receiving 2 doses of the Pfizer-BioNTech SARS-CoV-2 messenger RNA vaccine. Anti-SARS-CoV-2 spike (S) immunoglobulin (Ig)-G levels were evaluated to define cofactors influencing the immune response between the responder (anti-SARS-CoV-2 IgG level ≥0.8 U/mL) (n = 16) and nonresponder groups (anti-SARS-CoV-2 IgG level <0.8 U/mL) (n = 13). The kinetics of antibodies between 2 and 6 months after the second vaccination was also compared between the groups.
Results: KTx recipients with IgG levels ≥0.8 U/mL were younger (54 [interquartile range {IQR}, 46.5-61] years vs 65 [IQR, 55-71.5] years; P = .01), had been transplanted for a longer median time (1588 [IQR, 1382-4751] days vs 1034 [IQR, 548.5-1833] days; P = .02), and were more often treated with a lower mycophenolate mofetil dosage (765.6 ± 119.6 vs 1077 ± 76.9 mg; P = .04) than KTx recipients with IgG levels <0.8 U/mL. There was no significant difference in antibody titers between time periods after the second dose in the responder group. At the 6-month follow-up, a serologic response against the SARS-CoV-2 S was observed in 44.4% of KTx recipients in the nonresponder group.
Conclusions: More than 50% of KTx recipients developed a higher antibody response after the second dose of COVID-19 vaccination.
. 2022 May 31;S0041-1345(22)00382-7.
doi: 10.1016/j.transproceed.2022.05.002. Online ahead of print.
Evaluation of the Correlation Between Responders and Non-Responders to the Second Coronavirus Disease Vaccination In Kidney Transplant Recipients: A Retrospective Single-Center Cohort Study
Masatoshi Matsunami[SUP] 1 [/SUP], Tomo Suzuki[SUP] 2 [/SUP], Shinnosuke Sugihara[SUP] 3 [/SUP], Takumi Toishi[SUP] 3 [/SUP], Kanako Nagaoka[SUP] 3 [/SUP], Junko Fukuda[SUP] 3 [/SUP], Mamiko Ohara[SUP] 3 [/SUP], Yayoi Takanashi[SUP] 4 [/SUP], Atsuhiko Ochi[SUP] 5 [/SUP], Jun Yashima[SUP] 4 [/SUP], Hiroshi Kuji[SUP] 6 [/SUP], Kosei Matsue[SUP] 7 [/SUP]
Affiliations
- PMID: 35868872
- DOI: 10.1016/j.transproceed.2022.05.002
Abstract
Background: The immune response to COVID-19 vaccination in kidney transplant (KTx) recipients is significantly lower than that in healthy controls. We evaluated immune responses after the COVID-19 vaccine and their possible relationship with other cofactors in KTx recipients.
Methods: This retrospective single-center cohort study included 29 KTx recipients 2-8 weeks after receiving 2 doses of the Pfizer-BioNTech SARS-CoV-2 messenger RNA vaccine. Anti-SARS-CoV-2 spike (S) immunoglobulin (Ig)-G levels were evaluated to define cofactors influencing the immune response between the responder (anti-SARS-CoV-2 IgG level ≥0.8 U/mL) (n = 16) and nonresponder groups (anti-SARS-CoV-2 IgG level <0.8 U/mL) (n = 13). The kinetics of antibodies between 2 and 6 months after the second vaccination was also compared between the groups.
Results: KTx recipients with IgG levels ≥0.8 U/mL were younger (54 [interquartile range {IQR}, 46.5-61] years vs 65 [IQR, 55-71.5] years; P = .01), had been transplanted for a longer median time (1588 [IQR, 1382-4751] days vs 1034 [IQR, 548.5-1833] days; P = .02), and were more often treated with a lower mycophenolate mofetil dosage (765.6 ± 119.6 vs 1077 ± 76.9 mg; P = .04) than KTx recipients with IgG levels <0.8 U/mL. There was no significant difference in antibody titers between time periods after the second dose in the responder group. At the 6-month follow-up, a serologic response against the SARS-CoV-2 S was observed in 44.4% of KTx recipients in the nonresponder group.
Conclusions: More than 50% of KTx recipients developed a higher antibody response after the second dose of COVID-19 vaccination.